Regulation of aromatase expression in breast cancer treated with anastrozole neoadjuvant therapy.
about
Influence of CYP19A1 polymorphisms on the treatment of breast cancer with aromatase inhibitors: a systematic review and meta-analysis.A polymorphism at the 3'-UTR region of the aromatase gene is associated with the efficacy of the aromatase inhibitor, anastrozole, in metastatic breast carcinoma.miRNA clusters as therapeutic targets for hormone-resistant breast cancer.Rs1008805 polymorphism of CYP19A1 gene is associated with the efficacy of hormone therapy in stage I-II and operable stage III breast cancer.
P2860
Regulation of aromatase expression in breast cancer treated with anastrozole neoadjuvant therapy.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Regulation of aromatase expres ...... astrozole neoadjuvant therapy.
@ast
Regulation of aromatase expres ...... astrozole neoadjuvant therapy.
@en
type
label
Regulation of aromatase expres ...... astrozole neoadjuvant therapy.
@ast
Regulation of aromatase expres ...... astrozole neoadjuvant therapy.
@en
prefLabel
Regulation of aromatase expres ...... astrozole neoadjuvant therapy.
@ast
Regulation of aromatase expres ...... astrozole neoadjuvant therapy.
@en
P2093
P2860
P356
P1476
Regulation of aromatase expres ...... nastrozole neoadjuvant therapy
@en
P2093
Chiara Ghimenti
Enrico Grosso
Lea Regolo
Maria Scatolini
Maurizia Mello-Grand
P2860
P304
P356
10.3892/ETM.2012.878
P577
2012-12-24T00:00:00Z